JP2016521553A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016521553A5 JP2016521553A5 JP2016517733A JP2016517733A JP2016521553A5 JP 2016521553 A5 JP2016521553 A5 JP 2016521553A5 JP 2016517733 A JP2016517733 A JP 2016517733A JP 2016517733 A JP2016517733 A JP 2016517733A JP 2016521553 A5 JP2016521553 A5 JP 2016521553A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- segment
- influenza
- nucleotide
- position corresponding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 206010022000 influenza Diseases 0.000 claims description 84
- 239000002773 nucleotide Substances 0.000 claims description 82
- 125000003729 nucleotide group Chemical group 0.000 claims description 82
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims description 44
- 230000001086 cytosolic effect Effects 0.000 claims description 39
- 241000712461 unidentified influenza virus Species 0.000 claims description 37
- 229930024421 Adenine Natural products 0.000 claims description 34
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 claims description 34
- 229960000643 adenine Drugs 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 33
- 101710154606 Hemagglutinin Proteins 0.000 claims description 31
- 101710093908 Outer capsid protein VP4 Proteins 0.000 claims description 31
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 claims description 31
- 101710176177 Protein A56 Proteins 0.000 claims description 31
- 102000005348 Neuraminidase Human genes 0.000 claims description 28
- 108010006232 Neuraminidase Proteins 0.000 claims description 28
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims description 28
- 239000000185 hemagglutinin Substances 0.000 claims description 27
- 229940113082 thymine Drugs 0.000 claims description 22
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 21
- 241000700605 Viruses Species 0.000 claims description 21
- 229960005486 vaccine Drugs 0.000 claims description 17
- 210000004027 cell Anatomy 0.000 claims description 16
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 claims description 16
- 229940104302 cytosine Drugs 0.000 claims description 14
- 208000037797 influenza A Diseases 0.000 claims description 14
- 208000037798 influenza B Diseases 0.000 claims description 10
- 230000003612 virological effect Effects 0.000 claims description 7
- 108091092724 Noncoding DNA Proteins 0.000 claims description 5
- 241000712431 Influenza A virus Species 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108090000623 proteins and genes Proteins 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 2
- 241000713196 Influenza B virus Species 0.000 claims description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 2
- 239000004472 Lysine Substances 0.000 claims description 2
- 239000000427 antigen Substances 0.000 claims description 2
- 102000036639 antigens Human genes 0.000 claims description 2
- 108091007433 antigens Proteins 0.000 claims description 2
- 210000000991 chicken egg Anatomy 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims description 2
- 210000003501 vero cell Anatomy 0.000 claims description 2
- 210000002845 virion Anatomy 0.000 claims description 2
- 239000000277 virosome Substances 0.000 claims description 2
- 229940126581 whole-virion vaccine Drugs 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361832091P | 2013-06-06 | 2013-06-06 | |
| US61/832,091 | 2013-06-06 | ||
| EP13179013 | 2013-08-01 | ||
| EP13179013.1 | 2013-09-26 | ||
| PCT/IB2014/062030 WO2014195920A2 (en) | 2013-06-06 | 2014-06-06 | Influenza virus reassortment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016521553A JP2016521553A (ja) | 2016-07-25 |
| JP2016521553A5 true JP2016521553A5 (enExample) | 2017-07-20 |
Family
ID=48900885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016517733A Ceased JP2016521553A (ja) | 2013-06-06 | 2014-06-06 | インフルエンザウイルス再集合 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10329537B2 (enExample) |
| EP (1) | EP3004332A2 (enExample) |
| JP (1) | JP2016521553A (enExample) |
| KR (1) | KR20160014657A (enExample) |
| CN (1) | CN105722976A (enExample) |
| AU (1) | AU2014276418A1 (enExample) |
| BR (1) | BR112015030582A2 (enExample) |
| CA (1) | CA2914604A1 (enExample) |
| HK (1) | HK1222882A1 (enExample) |
| MX (1) | MX2015016755A (enExample) |
| SG (1) | SG11201509985XA (enExample) |
| WO (1) | WO2014195920A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013507990A (ja) | 2009-10-26 | 2013-03-07 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| ES2655051T3 (es) | 2011-08-26 | 2018-02-16 | Wisconsin Alumni Research Foundation | Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas |
| JP2016524915A (ja) | 2013-07-15 | 2016-08-22 | ウィスコンシン アルムニ リサーチ ファンデイション | Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| KR20180035807A (ko) | 2015-06-26 | 2018-04-06 | 세퀴러스 유케이 리미티드 | 항원적으로 매치된 인플루엔자 백신 |
| WO2017007839A1 (en) | 2015-07-06 | 2017-01-12 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| JP2019510481A (ja) | 2016-02-19 | 2019-04-18 | ウィスコンシン アルムニ リサーチ ファンデイション | ワクチン開発のための改善されたｂ型インフルエンザウイルス複製 |
| AU2017296857B2 (en) * | 2016-07-15 | 2019-03-14 | The Research Foundation For Microbial Diseases Of Osaka University | Reassortant influenza virus production method |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| CN108048476B (zh) * | 2017-11-21 | 2020-09-08 | 浙江迪福润丝生物科技有限公司 | 一种制备区分免疫和感染动物h9亚型禽流感疫苗株的方法及应用 |
| CN108018300B (zh) * | 2017-11-21 | 2020-08-28 | 浙江迪福润丝生物科技有限公司 | 区分免疫和感染动物h7亚型禽流感疫苗株及其制备方法和应用 |
| AU2019240068B2 (en) * | 2018-03-21 | 2025-03-13 | Aldevron, L.L.C. | Viral and non-viral nanoplasmid vectors with improved production |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| US11389523B2 (en) | 2018-08-20 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein |
| EP3914295A2 (en) | 2019-01-23 | 2021-12-01 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
| WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| CN113527443B (zh) * | 2020-04-16 | 2023-03-07 | 中国科学院微生物研究所 | 甲型流感病毒pb1蛋白t细胞表位多肽片段及其应用 |
| US20240209035A1 (en) * | 2021-04-15 | 2024-06-27 | Biorchestra Co., Ltd. | Polynucleotides capable of enhanced protein expression and uses thereof |
| CN114058742B (zh) * | 2022-01-18 | 2022-04-22 | 广州科方生物技术股份有限公司 | 一种引物探针组合物、包含其的试剂盒及其检测方法 |
| CN119452088A (zh) * | 2022-05-31 | 2025-02-14 | Vlp治疗日本公司 | 修饰疫苗设计开发 |
| CN116144612B (zh) * | 2022-12-08 | 2023-11-10 | 广州医科大学附属第一医院（广州呼吸中心） | 重组乙型流感病毒及其制备方法与应用 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| WO1995011700A1 (en) | 1993-10-29 | 1995-05-04 | Pharmos Corp. | Submicron emulsions as vaccine adjuvants |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE19612967A1 (de) | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| US6080725A (en) | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| PL355287A1 (en) | 1999-09-24 | 2004-04-05 | Smithkline Beecham Biologicals S.A. | Intranasal influenza virus vaccine |
| CA2401117C (en) | 2000-03-03 | 2010-06-29 | Juridical Foundation The Chemo-Sero-Therapeutic Research Institute | Cell usable in serum-free culture and suspension culture and process for producing virus for vaccine by using the cell |
| GB0024089D0 (en) | 2000-10-02 | 2000-11-15 | Smithkline Beecham Biolog | Novel compounds |
| EP1361890B1 (en) | 2001-02-23 | 2011-03-30 | GlaxoSmithKline Biologicals s.a. | Influenza vaccine formulations for intradermal delivery |
| WO2002067983A1 (en) | 2001-02-23 | 2002-09-06 | Glaxosmithkline Biologicals S.A. | Novel vaccine |
| MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
| EP1633312A4 (en) * | 2003-06-16 | 2012-09-26 | Medimmune Llc | INFLUENZA HEMAGGLUTININE AND NEURAMINIDASE VARIANTS |
| KR20110132416A (ko) | 2004-04-05 | 2011-12-07 | 화이자 프로덕츠 인코포레이티드 | 미세유체화된 수중유 유화액 및 백신 조성물 |
| WO2005113756A1 (en) | 2004-05-14 | 2005-12-01 | Glaxosmithkline Biologicals S.A. | Method |
| AU2005245943A1 (en) | 2004-05-20 | 2005-12-01 | Id Biomedical Corporation | Process for the production of an influenza vaccine |
| ES2526170T3 (es) | 2004-12-23 | 2015-01-07 | Medimmune, Llc | Línea celular MDCK no tumorigénica para propagar virus |
| US7691368B2 (en) | 2005-04-15 | 2010-04-06 | Merial Limited | Vaccine formulations |
| EP1917352A4 (en) | 2005-06-21 | 2009-03-25 | Medimmune Vaccines Inc | METHODS AND COMPOSITIONS FOR EXPRESSING HETEROLOGOUS PROTEASE |
| US8703095B2 (en) | 2005-07-07 | 2014-04-22 | Sanofi Pasteur S.A. | Immuno-adjuvant emulsion |
| ATE494906T1 (de) | 2005-11-01 | 2011-01-15 | Novartis Vaccines & Diagnostic | Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna |
| KR20080069232A (ko) | 2005-11-04 | 2008-07-25 | 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. | 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼 |
| FR2896162B1 (fr) | 2006-01-13 | 2008-02-15 | Sanofi Pasteur Sa | Emulsion huile dans eau thermoreversible |
| CN101528941B (zh) | 2006-04-19 | 2014-03-12 | 米迪缪尼有限公司 | 在犬细胞中表达负义病毒rna的方法和组合物 |
| CA2664619C (en) | 2006-10-12 | 2012-12-11 | Glaxosmithkline Biologicals S.A. | Immunogenic compositions comprising an oil-in-water emulsion adjuvant containing a reduced amount of squalene, tocol and an emulsifying agent |
| JP2011506264A (ja) | 2006-12-06 | 2011-03-03 | ノバルティス アーゲー | インフルエンザウイルスの４つの株に由来する抗原を含むワクチン |
| EP2045323A1 (en) | 2007-10-05 | 2009-04-08 | Avir Green Hills Biotechnology Research Development Trade Ag | Linear expression constructs for production of influenza virus particles |
| JP5836266B2 (ja) | 2009-05-21 | 2015-12-24 | ノバルティス アーゲー | 非内因性ｐｏｌＩプロモーターを使用した逆遺伝学 |
| BRPI1015053A2 (pt) * | 2009-06-24 | 2019-07-09 | Medicago Inc | partículas similares a vírus da influenza quiméricas compreendendo hemaglutinina |
| WO2011012999A1 (en) | 2009-07-31 | 2011-02-03 | Novartis Ag | Reverse genetics systems |
| KR20120083480A (ko) | 2009-10-20 | 2012-07-25 | 노파르티스 아게 | 바이러스 구제를 위한 개선된 역유전학 방법 |
| WO2013087945A2 (en) * | 2012-03-02 | 2013-06-20 | Novartis Ag | Influenza virus reassortment |
| MX360120B (es) * | 2012-08-03 | 2018-10-23 | Sanofi Pasteur | Produccion de virus infecciosos de influenza. |
-
2014
- 2014-06-06 CN CN201480044797.3A patent/CN105722976A/zh active Pending
- 2014-06-06 HK HK16110972.3A patent/HK1222882A1/zh unknown
- 2014-06-06 SG SG11201509985XA patent/SG11201509985XA/en unknown
- 2014-06-06 WO PCT/IB2014/062030 patent/WO2014195920A2/en not_active Ceased
- 2014-06-06 JP JP2016517733A patent/JP2016521553A/ja not_active Ceased
- 2014-06-06 BR BR112015030582A patent/BR112015030582A2/pt not_active Application Discontinuation
- 2014-06-06 US US14/896,348 patent/US10329537B2/en active Active
- 2014-06-06 CA CA2914604A patent/CA2914604A1/en not_active Abandoned
- 2014-06-06 AU AU2014276418A patent/AU2014276418A1/en not_active Abandoned
- 2014-06-06 EP EP14733369.4A patent/EP3004332A2/en not_active Withdrawn
- 2014-06-06 KR KR1020157035931A patent/KR20160014657A/ko not_active Withdrawn
- 2014-06-06 MX MX2015016755A patent/MX2015016755A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015119730A5 (enExample) | ||
| JP2016509864A5 (enExample) | ||
| EP1631663B1 (en) | High titer recombinant influenza viruses for vaccines and gene therapy | |
| JP6324725B2 (ja) | 発現系 | |
| Kaverin et al. | Intergenic HA–NA interactions in influenza A virus: postreassortment substitutions of charged amino acid in the hemagglutinin of different subtypes | |
| JP2020010711A (ja) | Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス | |
| US11427619B2 (en) | Methods of optimizing nucleotide sequences encoding engineered influenza proteins | |
| JP2016501020A5 (enExample) | ||
| CA2848117A1 (en) | Recombinant influenza virus highly expressing ha protein and preparation method and use thereof | |
| JP2011182797A5 (enExample) | ||
| WO2008156681A2 (en) | Adenoviral vectors for influenza virus production | |
| US20190203170A1 (en) | Avian Cells for Improved Virus Production | |
| Groth et al. | The genome of an influenza virus from a pilot whale: Relation to influenza viruses of gulls and marine mammals | |
| Li et al. | Screening of the high yield influenza B virus on MDCK cell and cloning of its whole genome | |
| Chen et al. | Partial and full PCR-based reverse genetics strategy for influenza viruses | |
| Shao et al. | An efficient and rapid influenza gene cloning strategy for reverse genetics system | |
| CN103118704B (zh) | 经修饰的病毒株及用于改善流感病毒的疫苗种子的产生的方法 | |
| Horimotob | Viruses–Applications in Research and Vaccine Design | |
| Horimoto et al. | Designing vaccines for pandemic influenza | |
| An et al. | Generation of highly productive and mammalian nonpathogenic recombinant H9N2 avian influenza viruses by optimization of 3’end promoter and NS genome | |
| CA2880409A1 (en) | Production of infectious influenza viruses | |
| Su et al. | Emergence and pandemic potential of avian influenza a (H7N9) virus | |
| JP2015530875A5 (enExample) | ||
| Keawcharoen et al. | Repository of Eurasian influenza A virus hemagglutinin and neuraminidase reverse genetics vectors and recombinant viruses | |
| CN116622650A (zh) | 一种自噬-溶酶体靶向病毒及其制备方法和应用 |